Millennium Management Amends X4 Pharma Stake, Signals Ownership Change

TL;DR

**Millennium Management just changed their X4 Pharma stake, watch for potential stock movement.**

AI Summary

Millennium Management LLC, a New York-based investment firm, filed an amended SC 13G/A on January 16, 2024, indicating a change in their ownership of X4 Pharmaceuticals, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous Schedule 13G, signals that Millennium Management LLC's stake in X4 Pharmaceuticals has likely decreased below the 5% threshold, or they are no longer required to report under Rule 13d-1(c). This matters to investors because a significant institutional investor reducing its stake could be interpreted as a loss of confidence in the company's future prospects, potentially impacting stock price.

Why It Matters

A major institutional investor like Millennium Management adjusting its position can influence market sentiment and potentially signal a shift in their outlook on X4 Pharmaceuticals' value.

Risk Assessment

Risk Level: medium — A large institutional investor reducing its stake can create selling pressure or signal underlying concerns, posing a moderate risk to current and prospective shareholders.

Analyst Insight

Investors should monitor X4 Pharmaceuticals' stock performance and look for further disclosures or news that might explain Millennium Management's adjusted position, as this could indicate a shift in the company's outlook.

Key Players & Entities

• Millennium Management LLC (company) — the reporting person and institutional investor
• X4 Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• January 16, 2024 (date) — the filing date of the SC 13G/A
• 98420X103 (other) — the CUSIP number for X4 Pharmaceuticals common stock

Forward-Looking Statements

• X4 Pharmaceuticals' stock price may experience short-term volatility due to the perceived change in institutional investor confidence. (X4 Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securiti

Filing Documents

• XFOR_SC13GA1.htm (SC 13G/A) — 78KB
• 0001273087-24-000017.txt ( ) — 80KB

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); CUSIP No. 98420X103 SCHEDULE 13G Page 6 of 10 (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J).

Ownership

Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: See response to Item 9 on each cover page. (b) Percent of Class: See response to Item 11 on each cover page. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote See response to Item 5 on each cover page. CUSIP No. 98420X103 SCHEDULE 13G Page 7 of 10 (ii) Shared power to vote or to direct the vote See response to Item 6 on each cover page. (iii) Sole power to dispose or to direct the disposition of See response to Item 7 on each cover page. (iv) Shared power to dispose or to direct the disposition of See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which Acquired

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group See Exhibit I.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 98420X103 SCHEDULE 13G Page 8 of 10 Exhibits: Exhibit I: Joint Filing Agreement, dated as of January 12, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. CUSIP No. 98420X103 SCHEDULE 13G Page 9 of 10 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct. Dated: January 12, 2024 MILLENNIUM MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM GROUP MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel /s/ Israel A. Englander Israel A. Englander CUSIP No. 98420X103 SCHEDULE 13G Page 10 of 10 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of X4 Pharmaceuticals, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: January 12, 2024 MILLENNIUM MANAGEMENT LLC By: /s/G

View Full Filing

View this SC 13G/A filing on SEC EDGAR